Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
DOI:
https://doi.org/10.2340/1651-226X.2024.24179Keywords:
Cancer, Immune checkpoint inhibitors, Immune related adverse events, Sex- and gender differences, Prospective trialAbstract
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in relation to sex- differentiation and their association with gender-specific factors are limited.
Aims: The primary objective of the G-DEFINER study is to compare the irAEs incidence in female and male patients who undergo ICI treatment. Secondary objectives are: to compare the irAEs incidence in pre- and postmenopausal female patients; to compare the irAEs incidence in female and male patients according to different clinical and gender-related factors (lifestyle, psychosocial, and behavioral factors). Exploratory objectives of the study are to compare and contrast hormonal, gene-expression, SNPs, cytokines, and gut microbiota profiles in relation to irAEs incidence in female and male patients.
Methods and Results: The patients are recruited from Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, St Vincent’s University Hospital, Ireland, Oslo University Hospital, Norway, and Karolinska Insitutet/Karolinska University Hospital, Sweden. The inclusion of patients was delayed due to the Covid pandemic, leading to a total of 250 patients recruited versus a planned number of 400 patients. Clinical and translational data will be analyzed.
Interpretation: The expected outcomes are to improve the management of cancer patients treated with ICIs, leading to more personalized clinical approaches that consider potential toxicity profiles. The real world nature of the trial makes it highly applicable for timely irAEs diagnosis.
Downloads
References
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044–60.
https://doi.org/10.3390/curroncol29050247 DOI: https://doi.org/10.3390/curroncol29050247
Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12:906251.
https://doi.org/10.3389/fonc.2022.906251 DOI: https://doi.org/10.3389/fonc.2022.906251
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24–34.
https://doi.org/10.1056/NEJMoa2109970 DOI: https://doi.org/10.1056/NEJMoa2109970
Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18:87.
https://doi.org/10.1186/s12916-020-01549-2 DOI: https://doi.org/10.1186/s12916-020-01549-2
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19:737–46.
https://doi.org/10.1016/S1470-2045(18)30261-4 DOI: https://doi.org/10.1016/S1470-2045(18)30261-4
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–37.
https://doi.org/10.1016/j.cell.2021.09.020 DOI: https://doi.org/10.1016/j.cell.2021.09.020
Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;30:S41–7.
https://doi.org/10.1016/j.bbi.2012.06.015 DOI: https://doi.org/10.1016/j.bbi.2012.06.015
Matthews T, Rasmussen LJH, Ambler A, Danese A, Eugen-Olsen J, Fancourt D, et al. Social isolation, loneliness, and inflammation: a multi-cohort investigation in early and mid-adulthood. Brain Behav Immun. 2024;115:727–36.
https://doi.org/10.1016/j.bbi.2023.11.022 DOI: https://doi.org/10.1016/j.bbi.2023.11.022
Nieman DC, Wentz LM. The compelling link between physical activity and the body’s defense system. J Sport Health Sci. 2019;8:201–17.
https://doi.org/10.1016/j.jshs.2018.09.009 DOI: https://doi.org/10.1016/j.jshs.2018.09.009
Liu YZ, Wang YX, Jiang CL. Inflammation: the common pathway of stress-related diseases. Front Hum Neurosci. 2017;11:316.
https://doi.org/10.3389/fnhum.2017.00316 DOI: https://doi.org/10.3389/fnhum.2017.00316
Cohen M, Shamay Y, Czamanski-Cohen J, Shulman K, Keren Rosenberg S, Abu-Amna M, et al. . Linkage between psychological factors and response to immune checkpoint inhibitor therapy: a preliminary study. Cells. 2023;12:2471.
https://doi.org/10.3390/cells12202471 DOI: https://doi.org/10.3390/cells12202471
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–38.
https://doi.org/10.1016/j.annonc.2022.10.001 DOI: https://doi.org/10.1016/j.annonc.2022.10.001
Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, et al. Advances in knowledge and management of immune-related adverse events in cancer immunotherapy. Front Endocrinol (Lausanne). 2022;13:779915.
https://doi.org/10.3389/fendo.2022.779915 DOI: https://doi.org/10.3389/fendo.2022.779915
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1008–19.
https://doi.org/10.1001/jamaoncol.2019.0393 DOI: https://doi.org/10.1001/jamaoncol.2019.0393
Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B. Research progress of biomarkers for immune checkpoint inhibitors on digestive system cancers. Front Immunol. 2022;13:810539.
https://doi.org/10.3389/fimmu.2022.810539 DOI: https://doi.org/10.3389/fimmu.2022.810539
Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget. 2017;8:99336–46.
https://doi.org/10.18632/oncotarget.22242 DOI: https://doi.org/10.18632/oncotarget.22242
Vavalà T, Catino A, Pizzutilo P, Longo V, Galetta D. Gender differences and immunotherapy outcome in advanced lung cancer. Int J Mol Sci. 2021;22:11942.
https://doi.org/10.3389/10.3390/ijms222111942
Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;111:772–81.
https://doi.org/10.1093/jnci/djz094 DOI: https://doi.org/10.1093/jnci/djz094
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38. DOI: https://doi.org/10.1038/nri.2016.90
https://doi.org/10.3390/ijms222111942 DOI: https://doi.org/10.3390/ijms222111942
Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20:442–7.
https://doi.org/10.1038/s41577-020-0348-8 DOI: https://doi.org/10.1038/s41577-020-0348-8
Qi S, Ngwa C, Morales Scheihing DA, Al Mamun A, Ahnstedt HW, Finger CE, et al. Sex differences in the immune response to acute COVID-19 respiratory tract infection. Biol Sex Differ. 2021;12:66.
https://doi.org/10.1186/s13293-021-00410-2 DOI: https://doi.org/10.1186/s13293-021-00410-2
Ross MT, Grapham DV, Coffey AJ, Scherer S., McLay K, Muzny D, et al. The DNA sequence of the human X chromosome. Nature. 2005;434:325–37.
https://doi.org/10.1038/nature03440 DOI: https://doi.org/10.1038/nature03440
Syrett CM & Anguera MC. When the balance is broken: X‐linked gene dosage from two X chromosomes and female‐biased autoimmunity. J Leukocyte Biol. 2019;106:919–32.
https://doi.org/10.1002/JLB.6RI0319-094R DOI: https://doi.org/10.1002/JLB.6RI0319-094R
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.
https://doi.org/10.1056/NEJMra1703481 DOI: https://doi.org/10.1056/NEJMra1703481
Bouchlaka MN, Murphy WJ. Impact of aging in cancer immunotherapy: the importance of using accurate preclinical models. Oncoimmunology. 2013;2:e27186.
https://doi.org/10.4161/onci.27186 DOI: https://doi.org/10.4161/onci.27186
Chong PP, Rubin JB, Abdullah M, Conforti F, Klein SL, Liu W. Editorial: differential efficacy of immune checkpoint inhibitors due to age and sex factors. Front Immunol. 2022;13:941254. DOI: https://doi.org/10.3389/fimmu.2022.941254
https://doi.org/ 10.3389/fimmu.2022.941254
Denton M, Prus S, Walters V. Gender differences in health: a Canadian study of the psychosocial, structural and behavioural determinants of health. Soc Sci Med. 2004;58:2585–600.
https://doi.org/10.1016/j.socscimed.2003.09.008 DOI: https://doi.org/10.1016/j.socscimed.2003.09.008
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, et al. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel). 2023;15:1629.
https://doi.org/10.3390/cancers15051629 DOI: https://doi.org/10.3390/cancers15051629
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Amer Statist Assoc. 1999;94:496–509.
https://doi.org/10.1080/01621459.1999.10474144 DOI: https://doi.org/10.1080/01621459.1999.10474144
Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013;9:215–34.
https://doi.org/10.1515/ijb-2012-0030 DOI: https://doi.org/10.1515/ijb-2012-0030
Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B (methodological). 1996:58:267–88.
https://doi.org/10.1111/j.2517-6161.1996.tb02080.x DOI: https://doi.org/10.1111/j.2517-6161.1996.tb02080.x
Tibshirani R. The lasso method for variable selection in the Cox Model. Stat Med. 1997;16:385–95.
https://doi.org/10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3 DOI: https://doi.org/10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
Kwon Y, Han K, Suh YJ, Jung I. Stability selection for LASSO with weights based on AUC. Sci Rep. 2023;13:5207.
https://doi.org/10.1038/s41598-023-32517-4 DOI: https://doi.org/10.1038/s41598-023-32517-4
Breiman L. Random forests. Mach Learn. 2001;45:5–32.
https://doi.org/10.1023/A:1010933404324 DOI: https://doi.org/10.1023/A:1010933404324
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57(1):289–300.
https://doi.org/10.1111/j.2517-6161.1995.tb02031.x DOI: https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
This work is licensed under a Creative Commons Attribution 4.0 International License.
Funding data
-
Horizon 2020
Grant numbers Gender-Net Plus;741874
